Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-08-13 Sale | 2024-08-15 5:06 pm | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 250,000 | $44.01 | $11,002,500 | 119,522 (Indirect) | View |
| 2024-08-13 Sale | 2024-08-15 5:01 pm | Keros Therapeutics Inc. | KROS | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director | 250,000 | $44.01 | $11,002,500 | 119,522 (Indirect) | View |
| 2023-11-04 Sale | 2024-01-08 4:43 pm | Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer | 40,000 | $45.29 | $1,811,600 | 53,622 (Direct) | View |
| 2023-06-08 Sale | 2023-06-12 4:13 pm | Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer | 40,000 | $46.61 | $1,864,239 | 207,244 (Direct) | View |
| 2020-04-13 Purchase | 2023-01-20 4:32 pm | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 1,191 | $20.98 | $24,987 | 575,492 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-11-08 Option Award | 2024-11-12 4:15 pm | N/A 2034-11-07 | Keros Therapeutics Inc. | KROS | CHYUNG YUNG H. Chief Medical Officer | 110,000 | $0 | 110,000 (Direct) | View |
| 2024-06-03 Option Award | 2024-06-05 4:11 pm | N/A 2034-06-02 | Keros Therapeutics Inc. | KROS | BIENAIME JEAN JACQUES Director | 17,600 | $0 | 17,600 (Direct) | View |
Ownership | 2024-06-05 4:10 pm | N/A N/A | Keros Therapeutics Inc. | KROS | BIENAIME JEAN JACQUES Director | 0 | $0 | 200 (Direct) | View |
| 2024-05-30 Option Award | 2024-06-03 4:15 pm | N/A 2034-05-29 | Keros Therapeutics Inc. | KROS | Seth Alpna Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-05-30 Option Award | 2024-06-03 4:15 pm | N/A 2034-05-29 | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-05-30 Option Award | 2024-06-03 4:15 pm | N/A 2034-05-29 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-05-30 Option Award | 2024-06-03 4:15 pm | N/A 2034-05-29 | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-05-30 Option Award | 2024-06-03 4:15 pm | N/A 2034-05-29 | Keros Therapeutics Inc. | KROS | GRAY MARY ANN Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-05-30 Option Award | 2024-06-03 4:15 pm | N/A 2034-05-29 | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-05-30 Option Award | 2024-06-03 4:15 pm | N/A 2034-05-29 | Keros Therapeutics Inc. | KROS | Farzan Nima Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-02-23 Option Award | 2024-02-23 5:07 pm | N/A 2034-02-22 | Keros Therapeutics Inc. | KROS | Seehra Jasbir CHIEF EXECUTIVE OFFICER | 125,000 | $0 | 125,000 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 8:41 pm | N/A 2034-02-12 | Keros Therapeutics Inc. | KROS | Seehra Jasbir CHIEF EXECUTIVE OFFICER | 125,000 | $0 | 125,000 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 8:40 pm | N/A 2034-02-12 | Keros Therapeutics Inc. | KROS | Regnante Keith CHIEF FINANCIAL OFFICER | 40,000 | $0 | 40,000 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 8:38 pm | N/A 2034-02-12 | Keros Therapeutics Inc. | KROS | Rovaldi Christopher CHIEF OPERATING OFFICER | 150,000 | $0 | 150,000 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 8:37 pm | N/A 2034-02-12 | Keros Therapeutics Inc. | KROS | Cooper Simon Peter CHIEF MEDICAL OFFICER | 40,000 | $0 | 40,000 (Direct) | View |
| 2024-01-04 Exercise | 2024-01-08 4:43 pm | N/A 2030-04-06 | Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer | 40,000 | $0 | 53,622 (Direct) | View |
| 2023-11-04 Exercise | 2024-01-08 4:43 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer | 40,000 | $16 | 53,622 (Direct) | View |
| 2023-06-08 Exercise | 2023-06-12 4:13 pm | N/A 2030-04-06 | Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer | 40,000 | $0 | 207,244 (Direct) | View |
| 2023-06-08 Exercise | 2023-06-12 4:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer | 40,000 | $16 | 207,244 (Direct) | View |
| 2023-06-06 Option Award | 2023-06-08 4:48 pm | N/A 2033-06-05 | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-06-06 Option Award | 2023-06-08 4:47 pm | N/A 2033-06-05 | Keros Therapeutics Inc. | KROS | Seth Alpna Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-06-06 Option Award | 2023-06-08 4:45 pm | N/A 2033-06-05 | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-06-06 Option Award | 2023-06-08 4:44 pm | N/A 2033-06-05 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-06-06 Option Award | 2023-06-08 4:42 pm | N/A 2033-06-05 | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-06-06 Option Award | 2023-06-08 4:41 pm | N/A 2033-06-05 | Keros Therapeutics Inc. | KROS | GRAY MARY ANN Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-06-06 Option Award | 2023-06-08 4:38 pm | N/A 2033-06-05 | Keros Therapeutics Inc. | KROS | Farzan Nima Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2023-05-01 Option Award | 2023-05-03 4:45 pm | N/A 2033-04-30 | Keros Therapeutics Inc. | KROS | Seth Alpna Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2023-04-08 Exercise | 2023-04-11 4:05 pm | N/A 2029-06-18 | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 4,000 | $0 | 297,943 (Direct) | View |
| 2023-04-08 Exercise | 2023-04-11 4:05 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 4,000 | $0.48 | 297,943 (Direct) | View |
| 2023-02-16 Option Award | 2023-02-17 4:19 pm | N/A 2033-02-15 | Keros Therapeutics Inc. | KROS | Rovaldi Christopher Chief Operating Officer | 100,000 | $0 | 100,000 (Direct) | View |
| 2023-02-16 Option Award | 2023-02-17 4:15 pm | N/A 2033-02-15 | Keros Therapeutics Inc. | KROS | Cooper Simon Peter Chief Medical Officer | 40,000 | $0 | 40,000 (Direct) | View |
| 2023-02-16 Option Award | 2023-02-17 4:14 pm | N/A 2033-02-15 | Keros Therapeutics Inc. | KROS | Regnante Keith Chief Financial Officer | 40,000 | $0 | 40,000 (Direct) | View |
| 2023-02-16 Option Award | 2023-02-17 4:13 pm | N/A 2033-02-15 | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 200,000 | $0 | 200,000 (Direct) | View |
| 2022-11-29 Exercise | 2022-11-30 4:42 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 7,176 | $0 | 1,226,412 (Indirect) | View |
| 2022-11-29 Exercise | 2022-11-30 4:42 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 7,176 | $0.0001 | 1,226,412 (Indirect) | View |
| 2022-11-29 Exercise | 2022-11-30 4:40 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 7,176 | $0 | 1,226,412 (Indirect) | View |
| 2022-11-29 Exercise | 2022-11-30 4:40 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 7,176 | $0.0001 | 1,226,412 (Indirect) | View |
| 2022-11-29 Exercise | 2022-11-30 4:38 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 7,176 | $0 | 1,226,412 (Indirect) | View |
| 2022-11-29 Exercise | 2022-11-30 4:38 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 7,176 | $0.0001 | 1,226,412 (Indirect) | View |
Ownership(A) | 2022-11-30 4:37 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 0 | $0 | 7,176 (Indirect) | View |
Ownership(A) | 2022-11-30 4:36 pm | N/A 2023-10-07 | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 0 | $0 | 7,176 (Indirect) | View |